<DOC>
	<DOCNO>NCT01065870</DOCNO>
	<brief_summary>This study patient locally advanced pancreatic cancer ( cancer involve local blood vessel remove without cut major blood vessel ) treat surgery . The purpose study assess safety benefit 6 three week cycle chemotherapy treatment consist gemcitabine , capecitabine docetaxel ( also call 'GTX ' ) . The patient fall two group . Group I venous involvement . Group II patient arterial involvement may also venous involvement . If arterial involvement , GTX follow 5 1/2 week radiation therapy gemcitabine capecitabine . After chemotherapy radiation treatment , participant may able surgery remove remain pancreatic cancer .</brief_summary>
	<brief_title>Neoadjuvant GTX With Chemoradiation Pancreatic Cancer ( Stage II/III )</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm adenocarcinoma pancreas ( When possible tissue evaluate Kras mutation patient evaluate BRCA p16 mutation . ) Locally advanced disease determine Endoscopic ultrasound , CT scan ( chest/abdomen/pelvis contrast ) , MRI scan ( abdomen gadolinium ) PET scan . No evidence metastatic disease CT scan ( chest/abdomen/pelvis contrast ) , MRI scan ( abdomen gadolinium ) PET scan . Unresectable tumor . ( reflect patient whose tumor abut , invade surround major vessel , either venous arterial ) No prior chemotherapy radiation therapy . Ineligible high priority national institutional study . Negative serum urine βHCG within 1 week start treatment nonpregnant , nonmenopausal female . Must underlie medical condition would make ineligible surgery , radiation therapy , chemotherapy . Complete Blood Count Complete Metabolic Profile : Absolute Neutrophil Count &gt; 1,500 μl White Blood Count &gt; 3,000/μl Platelet count &gt; 100,000/μl BUN &lt; 1.5 x normal Creatinine &lt; 1.5 normal Hemoglobin &gt; 8.0 g/dl Serum Albumin &gt; 3 mg/dl Total Bilirubin &lt; 3.0 mg/dl SGOT , SGPT , Alkaline Phosphatase &lt; 2.5 x ULN Informed consent : Each patient must completely aware nature his/her disease process must willingly give consent informed nature therapy , alternative , potential benefit , sideeffects , risk , discomfort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>